Severe community-acquired pneumonia compared to severe community-acquired Acinetobacter baumannii pneumonia in Reunion Island: A retrospective study.

Giacomo Rotini, Axel de Mangou, Agathe Combe, Amelie Renou, Chloe Combe, Radj Cally, Marie Lagrange-Xelot, Nicolas Allou, Guillaume Miltgen, Charles Vidal
Author Information
  1. Giacomo Rotini: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  2. Axel de Mangou: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  3. Agathe Combe: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  4. Amelie Renou: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  5. Chloe Combe: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  6. Radj Cally: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  7. Marie Lagrange-Xelot: Department of infectious and tropical disease, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  8. Nicolas Allou: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.
  9. Guillaume Miltgen: Department of microbiology, Felix Guyon University Hospital, UMR PIMIT, CNRS 9192, INSERM U1187, IRD 249, University of Reunion Island, Saint-Denis, Reunion, France.
  10. Charles Vidal: Department of intensive care medicine, Felix Guyon University Hospital, Saint-Denis, Reunion, France.

Abstract

Acinetobacter baumannii (Ab) has emerged in the last decades as a cause of community-acquired pneumonia (CAP) in tropical and subtropical regions. We previously conducted the first investigation on this topic in France with a case series of severe CAP-Ab in Reunion Island over an eight-year period. In the present work, we aim to highlight the specific aspects of CAP-Ab by comparing our case series with an historical cohort (PAC_RUN), obtained by retrospective chart review (2016-2021) of severe community-acquired pneumonia cases on Reunion Island, in which CAP-Ab was ruled out. During the study period, eight CAP-Ab cases were identified, giving an incidence of 0.1 cases per 100,000 people/year, and an incidence of 16.5 cases per 100,000 people/year for non-Ab-related CAP (n = 761). By comparing with non-Ab-related CAP, patients had more excessive alcohol use (75% vs. 25.6%, p = 0.005) and lower body mass index (21 vs. 24 kg/m, p = 0.004). Six cases (75%) of CAP-Ab occurred during the rainy season (p = 0.06). Mortality was higher (62.5% vs. 24.3%, p = 0.02) and time to death was shorter (median 2 days vs. 7, p = 0.009) in the CAP-Ab group. Bacteraemic pneumonia was strongly associated with CAP-Ab (62.5% vs. 15.7%, p = 0.004). Significant differences were found in the need for renal replacement therapy (75% vs. 17.2%, p < 0.001), catecholamine use (100% vs. 54.5%, p = 0.01) and use of invasive mechanical ventilation (100% vs. 62.7%, p = 0.03). Also, in the proportion of severe acute respiratory distress syndrome (62.5% vs. 23.2%, p = 0.02), septic shock (100% vs. 40.6%, p < 0.001), and cardiogenic shock (87.5% vs. 15.9%, p < 0.001). Compared to severe non-Ab-related CAP, severe CAP-Ab is characterised by higher mortality, associated with a high frequency of multiple organ failure. Excessive alcohol consumption and malnutrition seem to be risk factors. To improve outcomes, broader spectrum antibiotic therapy must be immediately proposed when CAP-Ab is suspected.

Keywords

References

  1. Med Mal Infect. 2011 May;41(5):221-8 [PMID: 21106313]
  2. Crit Care. 2014 Apr 01;18(2):R58 [PMID: 24690444]
  3. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67 [PMID: 31573350]
  4. PLoS One. 2017 Jul 14;12(7):e0180888 [PMID: 28708843]
  5. PLoS One. 2021 Jun 24;16(6):e0252206 [PMID: 34166406]
  6. PLoS One. 2016 Jul 08;11(7):e0158958 [PMID: 27391234]
  7. Sci Rep. 2023 Aug 28;13(1):14013 [PMID: 37640709]
  8. N Engl J Med. 2015 Jul 30;373(5):415-27 [PMID: 26172429]
  9. Clin Microbiol Infect. 2012 Nov;18(11):1097-103 [PMID: 22085042]
  10. Respirology. 2018 Jan;23(1):28-35 [PMID: 28763150]
  11. J Crit Care. 2000 Sep;15(3):85-90 [PMID: 11011820]
  12. Arch Intern Med. 1995 Aug 7-21;155(15):1649-54 [PMID: 7618989]
  13. Intern Med. 2019 Jan 15;58(2):301-305 [PMID: 30210104]
  14. Clin Microbiol Rev. 2008 Jul;21(3):538-82 [PMID: 18625687]
  15. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 [PMID: 17278083]
  16. Crit Care. 2020 Jul 14;24(1):434 [PMID: 32665030]
  17. Am J Respir Crit Care Med. 2018 Jul 1;198(1):58-66 [PMID: 29351007]
  18. Arch Intern Med. 2002 Mar 25;162(6):682-8 [PMID: 11911722]
  19. Chest. 2014 Oct;146(4):1038-1045 [PMID: 24901292]
  20. Clin Infect Dis. 2018 Oct 15;67(9):1455-1462 [PMID: 29741597]
  21. JAMA. 2016 May 24-31;315(20):2190-9 [PMID: 27209269]
  22. Respirology. 2009 Nov;14(8):1200-5 [PMID: 19909464]
  23. Am J Med. 1979 Jul;67(1):39-43 [PMID: 463916]
  24. Sci Rep. 2017 Nov 10;7(1):15279 [PMID: 29127419]
  25. BMC Infect Dis. 2020 Jan 15;20(1):45 [PMID: 31941459]
  26. Crit Care Med. 2006 Jun;34(6):1589-96 [PMID: 16625125]
  27. Int J Infect Dis. 2015 Aug;37:64-9 [PMID: 26093214]
  28. Circulation. 2017 Oct 17;136(16):e232-e268 [PMID: 28923988]
  29. Open Forum Infect Dis. 2018 Mar 10;5(3):ofy044 [PMID: 29564365]
  30. Microb Genom. 2019 Mar;5(3): [PMID: 30806611]
  31. Int J Infect Dis. 2005 Jan;9(1):15-20 [PMID: 15603991]
  32. Expert Rev Anti Infect Ther. 2015 May;13(5):567-73 [PMID: 25850806]
  33. Chest. 2001 Oct;120(4):1072-7 [PMID: 11591541]
  34. Am J Trop Med Hyg. 2024 Jun 4;111(1):136-140 [PMID: 38834085]
  35. Chest. 2006 Jan;129(1):102-9 [PMID: 16424419]
  36. Clin Infect Dis. 1992 Jan;14(1):83-91 [PMID: 1571467]
  37. Lancet. 2011 Apr 9;377(9773):1264-75 [PMID: 21435708]
  38. Am J Med. 2000 Oct 1;109(5):378-85 [PMID: 11020394]
  39. Clin Infect Dis. 2016 Apr 1;62(7):817-823 [PMID: 26747825]
  40. Am J Respir Crit Care Med. 2017 Dec 15;196(12):1610-1612 [PMID: 28475350]
  41. Diagn Microbiol Infect Dis. 2016 Jan;84(1):63-68 [PMID: 26603136]
  42. PLoS One. 2022 Apr 15;17(4):e0267184 [PMID: 35427402]
  43. JAMA. 1993 Dec 22-29;270(24):2957-63 [PMID: 8254858]
  44. Trop Med Int Health. 2025 Jan;30(1):43-50 [PMID: 39629888]
  45. Crit Care Med. 2017 Mar;45(3):486-552 [PMID: 28098591]
  46. J Clin Microbiol. 2002 Feb;40(2):685-6 [PMID: 11825997]
  47. Eur J Clin Microbiol Infect Dis. 2007 Dec;26(12):857-68 [PMID: 17701432]

MeSH Term

Humans
Community-Acquired Infections
Retrospective Studies
Acinetobacter baumannii
Male
Female
Reunion
Middle Aged
Acinetobacter Infections
Aged
Adult
Incidence
Anti-Bacterial Agents
Pneumonia, Bacterial
Risk Factors
Pneumonia

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0vsCAP-Abp = 0severepneumoniacases5%community-acquiredCAPReunion62AcinetobacterbaumanniiIslandnon-Ab-relateduse75%p < 0001100%tropicalcaseseriesperiodcomparingretrospectivestudyincidenceper100000people/yearalcohol6%004higher02associated157%therapy2%shockAbemergedlastdecadescausesubtropicalregionspreviouslyconductedfirstinvestigationtopicFranceeight-yearpresentworkaimhighlightspecificaspectshistoricalcohortPAC_RUNobtainedchartreview2016-2021ruledeightidentifiedgiving01165n = 761patientsexcessive25005lowerbodymassindex2124 kg/mSixoccurredrainyseason06Mortality243%timedeathshortermedian2 days7009groupBacteraemicstronglySignificantdifferencesfoundneedrenalreplacement17catecholamine5401invasivemechanicalventilation03Alsoproportionacuterespiratorydistresssyndrome23septic40cardiogenic879%ComparedcharacterisedmortalityhighfrequencymultipleorganfailureExcessiveconsumptionmalnutritionseemriskfactorsimproveoutcomesbroaderspectrumantibioticmustimmediatelyproposedsuspectedSeverecomparedIsland:community‐acquiredregion

Similar Articles

Cited By